Interventional Cardiology. Группа авторов
caliber to the human coronary artery. Twenty‐four hours after an intravenous injection of Prosense VM110, a NIRF molecular imaging agent that reports on cathepsin protease activity in atheroma, in vivo intravascular NIRF‐OCT was performed. NIRF revealed augmented protease activity in OCT‐defined atheroma, with substantial inflammation heterogeneity seen across atheroma (a,d). The OCT catheter is seen in the middle of the image; the NIRF signal intensity (representing quantitative protease inflammatory activity) is represented by a color scale bar mapped on to the luminal border. The NIRF‐OCT findings were confirmed by histology (H&E, middle column b and e), and cathepsin B immunohistochemistry (right column, c and f).
Source: Yoo et al. 2011 [135]. Reproduced with permission of Nature Publishing Group.
Clinical translation
NIRF‐OCT imaging system
Recently, investigators performed the first human coronary imaging studies of patients using a clinically approved NIRF‐OCT catheter [147]. While this catheter was used to detect plaque NIR autofluorescence, or NIRAF (no imaging agent was injected), the ability to safely acquired NIRF‐OCT images is a major step forward in realizing intracoronary molecular imaging. NIRAF itself may indicated the presence of intraplaque hemorrhage [148].
NIRF molecular imaging agents
In addition to having a clinically approved catheter, clinical NIRF molecular imaging agents will be required. A promising candidate is indocyanine green (ICG), an amphiphilic molecule that has been FDA‐approved for decades to study cardiac, hepatic, and retinal blood flow. In 2011, Vinegoni et al. [140] showed that ICG can unexpectedly target plaque macrophages and plaque lipid in areas of heightened endothelial permeability, and thus could be useful for clinical intracoronary NIRF molecular imaging of vulnerable plaques. This finding was recently confirmed by others [149], and recently in human carotid atheroma patients [150]. Beyond ICG, many targeted NIRF agents are expected to be available for arterial disease in the future, driven primarily by the field of cancer NIRF molecular imaging [151].
Interactive multiple choice questions are available for this chapter on www.wiley.com/go/dangas/cardiology
References
1 1 Huang D, Swanson EA, Lin CP, et al. Optical coherence tomography. Science 1991; 22: 1178–1181.
2 2 Brezinski ME, Tearney GJ, Bouma BE, et al. Imaging of coronary artery microstructure (in vitro) with optical coherence tomography. Am J Cardiol 1996; 77(1): 92–93.
3 3 Lowe HC, Narula J, Fujimoto JG, Jang I‐K. Intracoronary optical diagnostics current status, limitations, and potential. JACC Cardiovasc Interv 2011; 4(12): 1257–1270.
4 4 Raffel OC, Akasaka T, Jang I‐K. Cardiac optical coherence tomography. Heart 2008; 94(9): 1200–1210.
5 5 Choma M, Sarunic M, Yang C, Izatt J. Sensitivity advantage of swept source and Fourier domain optical coherence tomography. Opt Express 2003; 11(18): 2183–2189.
6 6 Hebsgaard L, Christiansen EH, Holm NR. Calibration of intravascular optical coherence tomography as presented in peer reviewed publications. Int J Cardiol 2014; 171(1): 92–93.
7 7 Foin N, Mari JM, Nijjer S, et al. Intracoronary imaging using attenuationc ompensated optical coherence tomography allows better visualisation of coronary artery diseases. Cardiovasc Revasc Med 2013; 14(3): 139–143.
8 8 Van Soest G, Bosch JG, van der Steen AFW. Alignment of intravascular optical coherence tomography movies affected by non‐uniform rotation distortion. Procç SPIE 6847, Coherence Domain Optical Methods and Optical Coherence Tomography in Biomedicine XII, 684721: 2008.
9 9 Van Soest G, Regar E, Goderie TPM, et al. Pitfalls in plaque characterization by OCT: image artifacts in native coronary arteries. JACC Cardiovasc Imaging 2011; 4(7): 810–813.
10 10 Tearney GJ, Regar E, Akasaka T, et al. Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: a report from the International Working Group for Intravascular Optical Coherence Tomography Standardization and Validation. J Am Coll Cardiol 2012; 59(12): 1058–1072.
11 11 Bezerra HG, Costa MA, Guagliumi G, et al. Intracoronary optical coherence tomography: a comprehensive review clinical and research applications. JACC Cardiovasc Interv 2009; 2(11): 1035–1046.
12 12 Elahi S, Mancuso JJ, Milner TE, Feldman MD. Sunflower artifact in OCT. JACC Cardiovasc Imaging 2011; 4(11): 1220–1221.
13 13 Waller BF, Orr CM, Slack JD, et al. Anatomy, histology, and pathology of coronary arteries: a review relevant to new interventional and imaging techniques. Part I. Clin Cardiol 1992; 15(6): 451–457.
14 14 Fulton WFM. The Coronary Arteries: Arteriography, Microanatomy, and Pathogenesis of Obliterative Coronary Artery Disease. C.C. Thomas; 1965.
15 15 Prati F, Regar E, Mintz GS, et al. Expert review document on methodology, terminology, and clinical applications of optical coherence tomography: physical principles, methodology of image acquisition, and clinical application for assessment of coronary arteries and atherosclerosis. Eur Heart J 2010; 31(4): 401–415.
16 16 Radu MD, Räber L, Garcia‐Garcia H, Serruys PW (eds) The Clinical Atlas of Intravascular Optical Coherence Tomography, 2013.
17 17 Yabushita H, Bouma BE, Houser SL, et al. Characterization of human atherosclerosis by optical coherence tomography. Circulation 2002; 106(13): 1640–1645.
18 18 Manfrini O, Mont E, Leone O, et al. Sources of error and interpretation of plaque morphology by optical coherence tomography. Am J Cardiol 2006; 98(2): 156–159.
19 19 Van Soest G, Goderie T, Regar E, et al. Atherosclerotic tissue characterization in vivo by optical coherence tomography attenuation imaging. J Biomed Opt 2010; 15(1): 011105.
20 20 Kume T, Akasaka T, Kawamoto T, et al. Assessment of coronary arterial thrombus by optical coherence tomography. Am J Cardiol 2006; 97(12): 1713–1717.
21 21 Jang I‐K, Tearney GJ, MacNeill B, et al. in vivo characterization of coronary atherosclerotic plaque by use of optical coherence tomography. Circulation 2005; 111(12): 1551–1555.
22 22 Burke AP, Farb A, Malcom GT, et al. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med 1997; 336(18): 1276–1282.
23 23 Kume T, Akasaka T, Kawamoto T, et al. Measurement of the thickness of the fibrous cap by optical coherence tomography. Am Heart J 2006; 152(4): 755.e1–4.
24 24 Kubo T, Imanishi T, Kashiwagi M, et al. Multiple coronary lesion instability in patients with acute myocardial infarction as determined by optical coherence tomography. Am J Cardiol 2010; 105(3): 318–322.
25 25 Kimura S, Kakuta T, Yonetsu T, et al. Clinical significance of echo signal attenuation on intravascular ultrasound in patients with coronary artery disease. Circ Cardiovasc Interv 2009; 2(5): 444–454.
26 26 Di Vito L, Agozzino M, Marco V, et al. Identification and quantification of macrophage presence in coronary atherosclerotic plaques by optical coherence tomography. Eur Heart J Cardiovasc Imaging 2015; 16(7): 807–813.
27 27 Tanaka A, Tearney GJ, Bouma BE. Challenges on the frontier of intracoronary imaging: atherosclerotic plaque macrophage measurement by optical coherence tomography. J Biomed Opt 2010; 15(1): 011104.
28 28 Falk E, Nakano M, Bentzon JF, et al. Update on acute coronary syndromes: the pathologists’ view. Eur Heart J 2013; 34(10): 719–728.
29 29 Vorpahl M, Nakano M, Virmani R. Small black holes in optical frequency domain imaging matches intravascular neoangiogenesis formation in histology. Eur Heart J 2010; 31(15): 1889.
30 30 Kitabata H, Tanaka A, Kubo T, et al. Relation of microchannel structure identified by optical coherence tomography to plaque vulnerability in patients with coronary artery disease. Am J Cardiol 2010; 105(12):